Conventional receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeted CAR-T cells not only lyse ROR1+ tumor cells but also attack ROR1+ normal stromal cells, which may cause therapeutic iatrogenic toxicity [123, 124]. This evidence concerns the gene ROR1 and neoplasm.